This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Top Analyst Reports for Novo Nordisk, Bank of America & Netflix
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), Bank of America Corporation (BAC) and Netflix, Inc. (NFLX).
J&J (JNJ) Seeks Expanded Use of Lung Cancer Drug Rybrevant
by Zacks Equity Research
J&J's (JNJ) sBLA seeks label expansion for Rybrevant plus chemotherapy to treat patients with EGFR-mutated NSCLC whose disease progressed on or after treatment with AstraZeneca's Tagrisso (osimertinib).
Should You Invest in the iShares U.S. Healthcare ETF (IYH)?
by Zacks Equity Research
Sector ETF report for IYH
13F Rundown: Tepper, Buffett, Druckenmiller
by Andrew Rocco
Stock Strategist Andrew Rocco divulges valuable insights from the world's best and brightest investors.
Should Vanguard High Dividend Yield ETF (VYM) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for VYM
Johnson & Johnson (JNJ) Down 2.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
by Zacks Equity Research
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, J&J and AbbVie
by Zacks Equity Research
Eli Lilly, Novo Nordisk, J&J and AbbVie are part of the Zacks Industry Outlook article.
4 Large Drug Stocks Likely to Sail Through Industry Woes
by Kinjel Shah
Drug, biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), J&J (JNJ) and AbbVie (ABBV) are worth retaining in your portfolio.
Should You Invest in the Vanguard Health Care ETF (VHT)?
by Zacks Equity Research
Sector ETF report for VHT
Bayer's (BAYRY) Q3 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Bayer (BAYRY) reports weaker-than-expected third-quarter 2023 results. Management maintains its 2023 outlook.
Halozyme (HALO) Q3 Earnings Top Estimates, Revenues Lag
by Zacks Equity Research
Halozyme's (HALO) third-quarter earnings beat estimates, while revenues miss the same. The company maintains revenue guidance for full-year 2023.
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
GSK Beats on Q3 Earnings and Sales, Raises 2023 Guidance
by Zacks Equity Research
GSK's revenues benefit from strong growth across the Specialty Medicines and Vaccines segments. The company raises guidance for earnings and sales on the back of strong RSV vaccine sales.
AbbVie (ABBV) Q3 Earnings Beat, Shares Down Despite Raised View
by Zacks Equity Research
AbbVie's (ABBV) third-quarter 2023 earnings and sales beat estimates. Though the company raised its EPS outlook for both 2023 and 2024, share price dives as some key drugs misses out on estimates.
Is iShares Core High Dividend ETF (HDV) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for HDV
Alkermes (ALKS) Down Despite Q3 Earnings & Revenue Beat
by Zacks Equity Research
Alkermes' (ALKS) earnings and revenues trump estimates in the third quarter of 2023. The company reiterates total revenue guidance for full-year 2023. Shares fall.
Drug, Biotech Stocks' Q3 Earnings Due on Oct 26: BMY, MRK, BPMC
by Ahan Chakraborty
Let's look at three biotech/drug companies, BMY, MRK and BPMC, slated to release quarterly results on Oct 26.
Charles River (CRL) Offers Access to Preclinical Cancer Research
by Zacks Equity Research
Charles River (CRL) contributes to 84 percent of the FDA-approved cancer medicines and provides partners with 16 oncology prospects.
Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Pharma Stock Roundup: JNJ Posts Upbeat Q3 Earnings, PFE, NVO Revise 2023 View
by Kinjel Shah
J&J (JNJ) reports strong third-quarter results. Merck's (MRK) new deal with Japan's Daiichi Sankyo to jointly develop the latter's three DXd ADC candidates.
JNJ Beats Q3 Earnings Estimates, Raises View: ETFs in Focus
by Sweta Killa
The world's biggest healthcare products maker continued with its long streak of earnings beat and lifted the full year outlook.
Is American Century U.S. Quality Value ETF (VALQ) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for VALQ
J&J (JNJ) Beats Q3 Earnings & Sales Estimates Post Spin-Off
by Zacks Equity Research
J&J (JNJ) beats estimates for third-quarter earnings and sales. It raises full-year sales and earnings guidance.
Retail Sales Increased More Than Expected
by Zacks Equity Research
Retail Sales Increased More Than Expected